Trinity Biotech, eine Perle mit Fantasie - 500 Beiträge pro Seite
eröffnet am 11.06.05 18:04:43 von
neuester Beitrag 11.06.05 18:16:01 von
neuester Beitrag 11.06.05 18:16:01 von
Beiträge: 4
ID: 986.841
ID: 986.841
Aufrufe heute: 0
Gesamt: 431
Gesamt: 431
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 39 Minuten | 5194 | |
| vor 1 Stunde | 5087 | |
| vor 41 Minuten | 4726 | |
| vor 1 Stunde | 3338 | |
| vor 48 Minuten | 3205 | |
| vor 1 Stunde | 2771 | |
| vor 55 Minuten | 2744 | |
| heute 15:17 | 2544 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.722,50 | +0,17 | 208 | |||
| 2. | 4. | 6,5460 | -2,53 | 80 | |||
| 3. | 6. | 10,760 | +2,28 | 72 | |||
| 4. | 14. | 19,158 | -24,80 | 66 | |||
| 5. | 5. | 163,04 | +1,30 | 56 | |||
| 6. | 18. | 31,02 | +4,80 | 54 | |||
| 7. | 10. | 16,800 | +5,00 | 46 | |||
| 8. | 2. | 0,2100 | +5,00 | 46 |
Feedback
Seit dem 1. Juni gibt es für 4 ehemalige Aktien 1 ADR:
Proposed Change to ADR Ratio and Application to List on NASDAQ National Market
DUBLIN, Ireland, June 1 /PRNewswire-FirstCall/ -- Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it is filing a notification of an ADR ratio change with the Securities & Exchange Commission (SEC) as part of a series of initiatives to improve its institutional investor relations programme and to enhance value for shareholders. These initiatives include an adjustment of the ratio of American Depositary Receipts (ADRs) to Ordinary Shares and an application to list on the NASDAQ National Market. Trinity is currently listed on the NASDAQ Small Cap Market and the Irish Stock Exchange.
The notification being filed with the SEC today describes Trinity`s application to adjust its ADR ratio (the ratio of ADRs to underlying Ordinary Shares) from 1 ADR: 1 Ordinary Share to 1 ADR: 4 Ordinary Shares. The purpose of the adjusted ratio of ADRs is a technical increase in Trinity`s share price (with a corresponding reduction in ADRs in issue) which will allow Trinity achieve a listing on the NASDAQ National Market.
Trinity currently meets all of the stringent requirements for NASDAQ National Market listing status with the exception of the minimum bid price requirement. As part of the application process, Trinity is adjusting the ADR ratio in order to meet the minimum bid price requirement of US$5. Trinity expects the ratio change to take effect tomorrow and a listing on the NASDAQ National Market to commence on Tuesday June 7th, 2005.
Ronan O`Caoimh, Trinity Biotech Chief Executive Officer, commented
Proposed Change to ADR Ratio and Application to List on NASDAQ National Market
DUBLIN, Ireland, June 1 /PRNewswire-FirstCall/ -- Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it is filing a notification of an ADR ratio change with the Securities & Exchange Commission (SEC) as part of a series of initiatives to improve its institutional investor relations programme and to enhance value for shareholders. These initiatives include an adjustment of the ratio of American Depositary Receipts (ADRs) to Ordinary Shares and an application to list on the NASDAQ National Market. Trinity is currently listed on the NASDAQ Small Cap Market and the Irish Stock Exchange.
The notification being filed with the SEC today describes Trinity`s application to adjust its ADR ratio (the ratio of ADRs to underlying Ordinary Shares) from 1 ADR: 1 Ordinary Share to 1 ADR: 4 Ordinary Shares. The purpose of the adjusted ratio of ADRs is a technical increase in Trinity`s share price (with a corresponding reduction in ADRs in issue) which will allow Trinity achieve a listing on the NASDAQ National Market.
Trinity currently meets all of the stringent requirements for NASDAQ National Market listing status with the exception of the minimum bid price requirement. As part of the application process, Trinity is adjusting the ADR ratio in order to meet the minimum bid price requirement of US$5. Trinity expects the ratio change to take effect tomorrow and a listing on the NASDAQ National Market to commence on Tuesday June 7th, 2005.
Ronan O`Caoimh, Trinity Biotech Chief Executive Officer, commented
INSTITUTIONAL
Total Number of Holders 26
% of Shares Outstanding 10.05%
Total Shares Held 1,396,654
Total Value of Holdings $9,245,849
Net Activity 374,757
Top 5 Holders Shares Held
PARADIGM CAPITA... 254,317
FMR CORP 227,325
HIGHBRIDGE CAPI... 182,102
PERRITT CAPITAL... 138,250
COURIER CAPITAL... 128,325
Total Number of Holders 26
% of Shares Outstanding 10.05%
Total Shares Held 1,396,654
Total Value of Holdings $9,245,849
Net Activity 374,757
Top 5 Holders Shares Held
PARADIGM CAPITA... 254,317
FMR CORP 227,325
HIGHBRIDGE CAPI... 182,102
PERRITT CAPITAL... 138,250
COURIER CAPITAL... 128,325
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 215 | ||
| 80 | ||
| 75 | ||
| 65 | ||
| 55 | ||
| 54 | ||
| 51 | ||
| 44 | ||
| 37 | ||
| 36 |
| Wertpapier | Beiträge | |
|---|---|---|
| 36 | ||
| 33 | ||
| 31 | ||
| 29 | ||
| 26 | ||
| 25 | ||
| 21 | ||
| 21 | ||
| 21 | ||
| 20 |
